Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Vivid Seats (SEAT) Asset Writedowns and Impairment (2025)

Vivid Seats has reported Asset Writedowns and Impairment over the past 1 years, most recently at -$320.4 million for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$320.4 million; the TTM value through Sep 2025 reached $320.4 million, changed N/A, while the annual FY2020 figure was $573.8 million, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2025 was -$320.4 million at Vivid Seats, down from $320.4 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $320.4 million in Q2 2025 and troughed at -$320.4 million in Q4 2025.